The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases

Topal, Fatih Alexander; Zuberbier, Torsten; Makris, Michaël; Hofmann, Maja

doi:10.1097/aci.0000000000000658

Cited by 27 publications

(25 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, Th17 cells and cytokine IL-17 are also involved in allergic diseases [ 20 ]. IL-17 antagonists have been approved to treat patients with psoriasis [ 21 ]. In studies on AD, patients with AD and children have significantly higher levels of Th17 cells and IL-17 in peripheral blood [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Candidate Genes of Allergic Dermatitis Are Associated with Immune Response

Jin

Deng

Wang³

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Allergic dermatitis (AD) is a common and burdensome inflammatory skin disease, and diagnosis is challenging. This study was conducted to identify candidate genes for AD diagnosis and underlying molecular mechanisms. Gene expression profiles were obtained from datasets GSE121212, GSE130588, and GSE157194. Use differential analysis to identify differentially expressed genes (DEGs) between AD and control. Use enrichment analysis to identify potential molecular dysregulation mechanisms. Comprehensive least absolute shrinkage and selection operator (LASSO) logistic regression, receiver operator characteristic (ROC) curve, and logistic regression analysis are used to identify candidate genes. In addition, ssGSEA and ImmPort database were used to identify AD-related immune response abnormalities. In this study, a total of 60 common genes were identified. Enrichment analysis found that these genes are mainly involved in Th17 cell immune and complement and coagulation cascades. LASSO regression analysis identified 18 feature genes, and screened genes with AUC >0.75 were selected as candidate genes. Finally, PLA2G4D, IFI6, AGR3, IGFL1, SPRR3, ATP13A5, SERPINB13, KRT16, HAS3, and CH25H were recognized as candidate genes and may be able to diagnose AD. PLA2G4D, CH25H, and IFI6 may be risk factors for AD based on logistic analysis. Furthermore, we identified the abnormalities of immune response activation in AD patients. Interestingly, PLA2G4D, CH25H, and IFI6 had positive correlations with immune cells and signaling pathways. PLA2G4D, CH25H, and IFI6 may be candidate diagnostic genes for AD. This may be related to their promotion of abnormal immune activation, especially Th17 cell immune.

show abstract

Section: Discussionmentioning

confidence: 99%

Candidate Genes of Allergic Dermatitis Are Associated with Immune Response

Jin

Deng

Wang³

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Danger signals from barrier disruption and microbial invasion trigger the production of additional keratinocyte-derived cytokines, such as IL-6, IL-23, and tumor necrosis factor (TNF)-α, which exhibit pro-inflammatory activities and promote the activation, differentiation, and recruitment of inflammatory cells to skin lesions [ 24 , 25 , 26 , 27 ]. The combination of IL-1β and IL-6, together with transforming growth factor-β (TGF-β), promotes Th17 cell activation, which plays an important part in early stages of AD [ 28 ].…”

Section: Active Participation Of Inflammatory Cytokines During Ad Evo...mentioning

confidence: 99%

Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets

Fania

Moretta

Antonelli

et al. 2022

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, which generally presents with intense itching and recurrent eczematous lesions. AD affects up to 20% of children and 10% of adults in high-income countries. The prevalence and incidence of AD have increased in recent years. The onset of AD mostly occurs in childhood, although in some cases AD may persist in adult life or even manifest in middle age (adult-onset AD). AD pathophysiology is made of a complex net, in which genetic background, skin barrier dysfunction, innate and adaptive immune responses, as well as itch contribute to disease development, progression, and chronicization. One of the most important features of AD is skin dehydration, which is mainly caused by filaggrin mutations that determine trans-epidermal water loss, pH alterations, and antigen penetration. In accordance with the “outside-inside” theory of AD pathogenesis, in a context of an altered epidermal barrier, antigens encounter epidermal antigen presentation cells (APCs), such as epidermal Langerhans cells and inflammatory epidermal dendritic cells, leading to their maturation and Th-2 cell-mediated inflammation. APCs also bear trimeric high-affinity receptors for immunoglobulin E (IgE), which induce IgE-mediated sensitizations as part of pathogenic mechanisms leading to AD. In this review, we discuss the role of cytokines in the pathogenesis of AD, considering patients with various clinical AD phenotypes. Moreover, we describe the cytokine patterns in patients with AD at different phases of the disease evolution, as well as in relation to different phenotypes/endotypes, including age, race, and intrinsic/extrinsic subtypes. We also discuss the outcomes of current biologics for AD, which corroborate the presence of multiple cytokine axes involved in the background of AD. A deep insight into the correlation between cytokine patterns and the related clinical forms of AD is a crucial step towards increasingly personalized, and therefore more efficient therapy.

show abstract

“…IL-17-producing cells are involved in various inflammatory diseases, such as psoriasis [ 70 , 71 , 72 , 73 , 74 ], asthma [ 75 , 76 , 77 , 78 , 79 ], and atopic dermatitis [ 80 , 81 , 82 ], and contribute to the development of host defense against microorganisms [ 83 , 84 , 85 , 86 ]. As the importance of IL-17-producing cells in the human body, IL-17-targeted biologics treatment is proven by the current advancement of this field.…”

Section: Clinical Sign and Biomarker For Drug Eruptionmentioning

confidence: 99%

Diagnostic Tools and Biomarkers for Severe Drug Eruptions

Yoshioka

Sawada

Nakamura

2021

IJMS

View full text Add to dashboard Cite

In accordance with the development of human technology, various medications have been speedily developed in the current decade. While they have beneficial impact on various diseases, these medications accidentally cause adverse reactions, especially drug eruption. This delayed hypersensitivity reaction in the skin sometimes causes a life-threatening adverse reaction, namely Stevens-Johnson syndrome and toxic epidermal necrolysis. Therefore, how to identify these clinical courses in early time points is a critical issue. To improve this problem, various biomarkers have been found for these severe cutaneous adverse reactions through recent research. Granulysin, Fas ligands, perforin, and granzyme B are recognized as useful biomarkers to evaluate the early onset of Stevens-Johnson syndrome and toxic epidermal necrolysis, and other biomarkers, such as miRNAs, high mobility group box 1 protein (HMGB1), and S100A2, which are also helpful to identify the severe cutaneous adverse reactions. Because these tools have been currently well developed, updates of the knowledge in this field are necessary for clinicians. In this review, we focused on the detailed biomarkers and diagnostic tools for drug eruption and we also discussed the actual usefulness of these biomarkers in the clinical aspects based on the pathogenesis of drug eruption.

show abstract

The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases

Cited by 27 publications

References 77 publications

Candidate Genes of Allergic Dermatitis Are Associated with Immune Response

Candidate Genes of Allergic Dermatitis Are Associated with Immune Response

Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets

Diagnostic Tools and Biomarkers for Severe Drug Eruptions

Contact Info

Product

Resources

About